PMC6387689_01
PMC6387689_02
Timeline with the estimated glomerular filtration rate (eGFR) and diameters of target lymph nodal metastases.
CRIONM2019-3452762.001.jpg
PMC6387689_02_CRIONM2019-3452762.001.jpg
fig1
Despite the development of ESRD, we decided to continue treatment with atezolizumab, given the absence of therapeutic options and in agreement with the patient and his relatives.  Figure 1 summarized the timeline with the eGFR and diameters of target lymph node metastases.
PMC6387689_03
Computed tomography (CT) images (a) before and (b) after 3 administrations of atezolizumab showing a significant decrease in the size of lymph nodal metastasis.
CRIONM2019-3452762.002.jpg
PMC6387689_03_CRIONM2019-3452762.002.jpg
fig2
In July 2017, the computed tomography (CT) scan without iodate contrast showed a partial response, with a volumetric reduction of about 30-70% of the lymph nodal and left adrenal gland metastases (Figure 2).